(R)-tert-Butyl (1-(2-fluorobenzyl)pyrrolidin-3-yl)carbamate

Catalog No. :
ACPAIF395
CAS No. :
876162-21-9
Molecular Formula :
C16H23FN2O2
Molecular Weight :
294.37

IUPAC Name:tert-butyl (R)-(1-(2-fluorobenzyl)pyrrolidin-3-yl)carbamate

(R)-tert-Butyl (1-(2-fluorobenzyl)pyrrolidin-3-yl)carbamate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g97%$292.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(R)-tert-Butyl (1-(2-fluorobenzyl)pyrrolidin-3-yl)carbamate
IUPAC Nametert-butyl (R)-(1-(2-fluorobenzyl)pyrrolidin-3-yl)carbamate
MDL No.MFCD17014247
Molecular FormulaC16H23FN2O2
Molecular Weight294.37
SMILESO=C(OC(C)(C)C)N[C@H]1CN(CC2=CC=CC=C2F)CC1
InChI KeyQIVAXTCJLWVJKN-CYBMUJFWSA-N
Synonym(R)-tert-Butyl 1-(2-fluorobenzyl)pyrrolidin-3-ylcarbamate;tert-butyl [(3R)-1-(2-fluorobenzyl)-3-pyrrolidinyl]carbamate;Carbamic acid, [(3R)-1-[(2-fluorophenyl)methyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI)
CAS No.876162-21-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACPAIF395 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBZXE159 route compound structure diagram
    ACBZXE1591416450-63-9 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACPAIF395 route product structure diagram
    ACPAIF395876162-21-9
Inquiry

2. ACPAIF395 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBZXE159 route compound structure diagram
    ACBZXE1591416450-63-9 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACPAIF395 route product structure diagram
    ACPAIF395876162-21-9
Inquiry

Comments (0)